These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 36940892)

  • 1. Lipid lowering combination therapy: From prevention to atherosclerosis plaque treatment.
    Masana L; Plana N; Andreychuk N; Ibarretxe D
    Pharmacol Res; 2023 Apr; 190():106738. PubMed ID: 36940892
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Effects of Statins, Ezetimibe, PCSK9-Inhibitors, Inclisiran, and Icosapent Ethyl on Platelet Function.
    Di Costanzo A; Indolfi C; Sorrentino S; Esposito G; Spaccarotella CAM
    Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511498
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Modern lipid-lowering drugs-A means to counter the problem of undertreatment?].
    Katzmann JL; Laufs U
    Inn Med (Heidelb); 2022 Dec; 63(12):1316-1322. PubMed ID: 35391570
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of Hypercholesterolemia, Appropriateness of Therapeutic Approaches and New Drugs in Patients with High Cardiovascular Risk.
    Agabiti Rosei E; Salvetti M
    High Blood Press Cardiovasc Prev; 2016 Sep; 23(3):217-30. PubMed ID: 27567901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.
    Schmidt AF; Carter JL; Pearce LS; Wilkins JT; Overington JP; Hingorani AD; Casas JP
    Cochrane Database Syst Rev; 2020 Oct; 10(10):CD011748. PubMed ID: 33078867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease.
    Cannon CP; Khan I; Klimchak AC; Reynolds MR; Sanchez RJ; Sasiela WJ
    JAMA Cardiol; 2017 Sep; 2(9):959-966. PubMed ID: 28768335
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent Updates on the Use of PCSK9 Inhibitors in Patients with Atherosclerotic Cardiovascular Disease.
    Dixon DL; Pamulapati LG; Bucheit JD; Sisson EM; Smith SR; Kim CJ; Wohlford GF; Pozen J
    Curr Atheroscler Rep; 2019 Mar; 21(5):16. PubMed ID: 30877491
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-density lipoprotein cholesterol lowering treatment: the current approach.
    Crismaru I; Pantea Stoian A; Bratu OG; Gaman MA; Stanescu AMA; Bacalbasa N; Diaconu CC
    Lipids Health Dis; 2020 May; 19(1):85. PubMed ID: 32375792
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Additive effects of ezetimibe, evolocumab, and alirocumab on plaque burden and lipid content as assessed by intravascular ultrasound: A PRISMA-compliant meta-analysis.
    Liang D; Li C; Tu Y; Li Z; Zhang M
    Medicine (Baltimore); 2022 Oct; 101(41):e31199. PubMed ID: 36254013
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship Between Low-Density Lipoprotein Cholesterol, Free Proprotein Convertase Subtilisin/Kexin Type 9, and Alirocumab Levels After Different Lipid-Lowering Strategies.
    Rey J; Poitiers F; Paehler T; Brunet A; DiCioccio AT; Cannon CP; Surks HK; Pinquier JL; Hanotin C; Sasiela WJ
    J Am Heart Assoc; 2016 Jun; 5(6):. PubMed ID: 27287699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PCSK9 inhibitors and ezetimibe for the reduction of cardiovascular events: a clinical practice guideline with risk-stratified recommendations.
    Hao Q; Aertgeerts B; Guyatt G; Bekkering GE; Vandvik PO; Khan SU; Rodondi N; Jackson R; Reny JL; Al Ansary L; Van Driel M; Assendelft WJJ; Agoritsas T; Spencer F; Siemieniuk RAC; Lytvyn L; Heen AF; Zhao Q; Riaz IB; Ramaekers D; Okwen PM; Zhu Y; Dawson A; Ovidiu MC; Vanbrabant W; Li S; Delvaux N
    BMJ; 2022 May; 377():e069066. PubMed ID: 35508320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention.
    Michaeli DT; Michaeli JC; Albers S; Boch T; Michaeli T
    Am J Cardiovasc Drugs; 2023 Sep; 23(5):477-495. PubMed ID: 37486464
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipid lowering therapy in primary and secondary prevention in Austria: are LDL-C goals achieved? : Results from the DA VINCI study.
    Siostrzonek P; Brath H; Zweiker R; Drexel H; Hoelzl R; Hemetsberger M; Ray KK
    Wien Klin Wochenschr; 2022 Apr; 134(7-8):294-301. PubMed ID: 34870742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Network Meta-Analysis of Randomized Trials Evaluating the Comparative Efficacy of Lipid-Lowering Therapies Added to Maximally Tolerated Statins for the Reduction of Low-Density Lipoprotein Cholesterol.
    Toth PP; Bray S; Villa G; Palagashvili T; Sattar N; Stroes ESG; Worth GM
    J Am Heart Assoc; 2022 Sep; 11(18):e025551. PubMed ID: 36073669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-Effectiveness of Icosapent Ethyl, Evolocumab, Alirocumab, Ezetimibe, or Fenofibrate in Combination with Statins Compared to Statin Monotherapy.
    Michaeli DT; Michaeli JC; Boch T; Michaeli T
    Clin Drug Investig; 2022 Aug; 42(8):643-656. PubMed ID: 35819632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Umbrella Review on Non-Statin Lipid-Lowering Therapy.
    Beshir SA; Hussain N; Elnor AA; Said ASA
    J Cardiovasc Pharmacol Ther; 2021 Sep; 26(5):437-452. PubMed ID: 33836639
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Statins plus ezetimibe in the era of proprotein convertase subtilisin/ kexin type 9 inhibitors.
    De Luca L; Corsini A; Uguccioni M; Colivicchi F
    Kardiol Pol; 2020 Sep; 78(9):850-860. PubMed ID: 32716152
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Hypercholesterolemia and cardiovascular risk].
    Sinning D; Landmesser U
    Dtsch Med Wochenschr; 2023 Aug; 148(16):1025-1032. PubMed ID: 37541292
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patients With High Cardiovascular Risk as Candidates to Bempedoic Acid, After Treatment With Statins, Ezetimibe and PCSK9 Inhibitors: An Estimation and Cost-Effectiveness Analysis.
    Seijas-Amigo J; Cordero A; Olmo RF; Cortez Quiroga GA; Fácila L; Salgado-Barreira Á; Reyes-Santías F; Romero-Menor C; Murillo JR; Rodríguez-Mañero M; Bello Mora MC; Valle A; Sandin M; Pamias RF; Bañeras J; García PB; Lorenzo MC; Sánchez-Alvarez S; López-Rodríguez L; González-Juanatey JR
    J Cardiovasc Pharmacol; 2023 Jan; 81(1):70-75. PubMed ID: 36219195
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Uptake of non-statin lipid-lowering therapies for secondary prevention in community practice.
    Bradley CK; Kolkailah AA; Shah NP; Page CB; Peterson ED; Navar AM
    J Clin Lipidol; 2023; 17(3):412-414. PubMed ID: 37029056
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.